A multinational real-world study of onabotulinumtoxinA in patients with overactive bladder demonstrates reduction in urinary symptoms and an improvement in quality of life along with a reduction in reliance on incontinence products

Summary Introduction: Pelvic floor muscle training (PFMT) involves the contraction of the puborectal, anal sphincter and external urethral muscles, inhibiting the detrusor contraction, what justify its use in the treatment of overactive bladder (OAB) symptoms. Objective: To verify the effects of isolated PFMT on the symptoms of OAB. Method: Prospective clinical trial with 27 women with mixed urinary incontinence (MUI), with predominance of OAB symptoms and loss ≥ 2 g in the pad test. It was evaluated: pelvic floor muscles (PFMs) function (digital palpation and manometry); urinary symptoms (nocturia, frequency and urinary loss); degree of discomfort of OAB symptoms; and quality of life (Incontinence Quality-of-Life Questionnaire [I-QoL]). The PFMT program consisted of 24 outpatient sessions (2x/week + home PFMT). The Mann-Whitney and Wilcoxon tests (with a significance level of 5%) were used to analyse the data. Results: There was a significant improvement of the urinary symptoms to the pad test (5.8±9.7, p<0.001), urinary loss (0.7±1.1, p=0.005) and nocturia (0.8±0.9, p=0.011). Reduction in the degree of discomfort of urinary symptoms was observed according to OAB-V8 questionnaire (10.0±7.7, p=0.001). There were also significant results in PFMs function: Oxford (3.6±0.9, p=0.001), endurance (5.2±1.8, p<0.001), fast (8.9±1.5, p<0.001) and manometry (26.6±15.8, p=0.003). In addition, quality of life had a significant improvement in the three domains evaluated by I-QoL. Conclusion: The PFMT without any additional guidelines improves the symptomatology, the function of PFMs and the quality of life of women with OAB symptoms.

Download Full-text

Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1419170 ◽

2018 ◽

Vol 34 (5) ◽

pp. 785-793 ◽

Cited By ~ 6

Author(s):

Robert Freeman ◽

Steve Foley ◽

José Rosa Arias ◽

Eduardo Vicente ◽

Robert Grill ◽

...

Keyword(s):

Quality Of Life ◽

Overactive Bladder ◽

Real World ◽

Treatment Satisfaction

Download Full-text

Association between age and low risk of clean intermittent catheterisation with onabotulinumtoxinA in overactive bladder patients with accompanying improvements in urinary symptoms and quality of life

European Urology Supplements ◽

10.1016/s1569-9056(17)30624-3 ◽

2017 ◽

Vol 16 (3) ◽

pp. e985-e986

Author(s):

M. Drake ◽

K. Everaert ◽

E. Rovner ◽

R. Dmochowski ◽

D. Ginsberg ◽

...

Keyword(s):

Quality Of Life ◽

Overactive Bladder ◽

Low Risk ◽

Urinary Symptoms ◽

Intermittent Catheterisation ◽

Clean Intermittent Catheterisation

Download Full-text

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice

International Urogynecology Journal ◽

10.1007/s00192-020-04423-0 ◽

2020 ◽

Vol 32 (1) ◽

pp. 65-74

Author(s):

Rizwan Hamid ◽

Maria-Fernanda Lorenzo-Gomez ◽

Heinrich Schulte-Baukloh ◽

Amin Boroujerdi ◽

Anand Patel ◽

...

Keyword(s):

Clinical Practice ◽

Overactive Bladder ◽

Real World ◽

Randomized Clinical Trials ◽

Time Frame ◽

Urinary Symptoms ◽

Treatment Benefit ◽

Treatment Procedures ◽

Incontinence Products ◽

Normal Clinical Practice

Abstract Introduction and hypothesis In randomized clinical trials onabotulinumtoxinA was demonstrated to be an effective and well-tolerated treatment for overactive bladder (OAB) with urinary incontinence (UI). However, data reporting onabotulinumtoxinA use in everyday clinical practice are limited. Here, we present the results from a large, first-of-its-kind real-world study in patients with OAB. Methods This was a prospective, observational, multinational study (GRACE; ClinicalTrials.gov, NCT02161159) performed in four European countries. Patients (N = 504) aged ≥ 18 years with OAB inadequately managed with ≥ 1 anticholinergic received onabotulinumtoxinA per their physician’s normal clinical practice. Results Physicians primarily used rigid cystoscopes for onabotulinumtoxinA injection; anesthesia/analgesia was utilized during most treatment procedures. Significant reductions in UI episodes/day from baseline to weeks 1 and 12 were observed as well as in micturition, urgency, and nocturia episodes/day. These improvements in urinary symptoms corresponded to higher scores on the treatment benefit scale at week 12. The use of other OAB medications dropped from baseline to weeks 1 and 12 and was sustained to week 52, which paralleled a reduction in the number of incontinence products used during that time frame. Adverse reactions were reported in 2.6% of patients throughout the study. Conclusions In this real-world study, significant improvements in urinary symptoms were seen following onabotulinumtoxinA treatment as early as week 1 and sustained to at least week 12. This was accompanied by a reduced reliance upon incontinence products and reduction in concomitant OAB medication use. OnabotulinumtoxinA was well tolerated with no new safety signals.

Download Full-text